Primary Percutaneous Coronary Intervention Clinical Trial
Official title:
Influence Of Incomplete Revascularization on Long-Term Outcomes After Primary Percutaneous Coronary Intervention (PPCI). A Single Center Real-Life Retrospective Analysis
| Verified date | April 2020 |
| Source | Assiut University |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
evaluate the influence of incomplete revascularization during the index hospitalization on in-hospital and long-term outcomes in STEMI patients undergoing PPCI in Assiut University heart hospital.
| Status | Completed |
| Enrollment | 3200 |
| Est. completion date | December 30, 2019 |
| Est. primary completion date | December 1, 2019 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | 19 Years and older |
| Eligibility |
Inclusion Criteria: All Patients aged >18 years with STEMI admitted to Assiut University Heart hospital and underwent successful PPCI between January 2016 to December 2019 were recruited. Selection of patients for primary PCI was as per guideline recommendations. - Exclusion Criteria: - Patients with incomplete data. - Patients with previous coronary artery bypass grafting (CABG). - Patients presenting with cardiogenic shock, cardiac arrest or pulmonary edema. - Mechanical complications of MI; namely VSD, wall rupture, mitral regurgitation secondary to papillary muscle or chordal rupture. - Patients with unsuccessful PPCI with a final TIMI flow = I in infarct related artery. - Patients with a significant co-morbidity reducing life expectancy to <1 year as patients with advanced liver diseases, cerebrovascular diseases, malignancy and chronic lung diseases that could affect patient prognosis |
| Country | Name | City | State |
|---|---|---|---|
| n/a | |||
| Lead Sponsor | Collaborator |
|---|---|
| Amany Edward Ramzy |
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Mace | All the patients will be reviewed for during hospital admission to record major acute cardiac events (MACE). Only the most serious event of major adverse cardiac events will be used to calculate the cumulative major adverse cardiac events per patient according to the following sequence: (death > heart failure > recurrent non-fatal MI > serious secondary arrhythmia necessitating DC shock> recurrent or refractory angina. MACE will be reported according to the standard definitions | between January 2016 to December 2019 were recruited |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02023983 -
Verification of the Safety of Early Discharge in Patients After Acute ST-segment Myocardial Infarction
|
N/A | |
| Recruiting |
NCT01860079 -
Early Discharge After Primary Percutaneous Coronary Intervention
|
N/A | |
| Completed |
NCT01152138 -
Closed Versus Open Cells Stent for Acute Myocardial Infarction
|
N/A | |
| Recruiting |
NCT03406819 -
Prevention of Coronary Slow Flow or No-Reflow During PPCI in Patients With Acute STEMI
|
N/A | |
| Recruiting |
NCT05510661 -
Use of Export in Primary Percutaneous Coronary Intervention
|
N/A | |
| Completed |
NCT03146858 -
Prolonged Enoxaparin In Primary Percutaneous Coronary Intervention; A Pilot Pharmacodynamic Study
|
Phase 4 | |
| Not yet recruiting |
NCT01158846 -
Bivalirudin/Prasugrel Versus Abciximab/Clopidogrel in Patients Presenting With STEMI
|
Phase 4 | |
| Active, not recruiting |
NCT03735719 -
Biomarkers for Risk Stratification After STEMI
|